ROCK HILL, South Carolina, October 26, 2023 – Today, 3D Systems (NYSE:DDD) announced Charles (Chuck) Hull, its co-founder and chief technology officer for regenerative medicine, has received the National Medal of Technology and Innovation (NMTI). Established in 1980, the NMTI is the United States’ highest honor for technological achievement, awarded by the President of the United States for outstanding contributions to America’s economic, environmental, and social well-being. Mr. Hull is being honored for the invention, development, and commercialization of Stereolithography (SLA), which launched the 3D printing industry, and for continuing innovation and leadership in additive manufacturing technology. He received the honor from President Joseph Biden at a ceremony held at The White House on Tuesday, October 24, 2023.
President Biden awards Charles W. Hull the National Medal of Technology and Innovation during an awards ceremony in the East Room of The White House, Oct. 24, 2023. (Photo courtesy of Ryan K. Morris and The National Science & Technology Medals Foundation)
Mr. Hull was Vice President of Engineering at UVP, Inc. (now owned by Analytik Jena), a company that manufactures ultraviolet light sources for industrial and scientific applications when he began working on a way to fuse UV resins into three-dimensional structures to create product prototypes. In 1983, he produced the first 3D-printed part, an eye wash cup, using Stereolithography. Mr. Hull applied for a patent for this technology, and in 1986 he co-founded 3D Systems through which the SLA-1, the first 3D printer, was commercialized. With the founding of 3D Systems, he initiated the 3D printing industry.
In 2014, Mr. Hull was inducted into the National Inventors Hall of Fame at the United States Patent and Trademark Office for his globally impactful and transformative work inventing and pioneering 3D printing. The same year, he received the European Patent Office’s prestigious European Inventor Award in the non-European countries category for his contributions to technological progress and the advancement of society. In 2016 Mr. Hull received the Manufacturing Leadership Lifetime Achievement Award from Frost & Sullivan’s Manufacturing Leadership Council, and The American Society of Mechanical Engineers (ASME) honored him and named the SLA-1, the first commercial 3D printer, a Historic Mechanical Engineering Landmark. He also received The Economist’s prestigious 2013 Innovation Award, recognizing significant contributions across the fields of science and technology. Mr. Hull is a named inventor on 85 United States patents, plus numerous other patents around the world in the fields of ion optics and 3D printing.
3D Systems remains a leader in innovation with state-of-the-art production 3D printers, materials, software, and application experts that have changed how products are manufactured and healthcare is delivered. As 3D Systems’ Chief Technology Officer for Regenerative Medicine, Mr. Hull continues to bring his pioneering spirit to the next frontier of 3D printing — bioprinting. He leads the 3D Systems team collaborating with United Therapeutics in a joint development program to establish an unlimited supply of human lungs, requiring no immunosuppression, potentially allowing patients with end-stage lung disease to benefit from an unlimited supply of tolerable, transplantable organs.
“On behalf of the entire company, I congratulate Chuck as a recipient of the National Medal of Technology and Innovation,” said Dr. Jeffrey Graves, president & CEO, 3D Systems. “He has had a remarkable career with his efforts not only changing the trajectory of manufacturing but also impacting the human condition by changing how healthcare is delivered. Chuck’s invention of Stereolithography gave birth to an industry and since that time, the number of 3D printing technologies has proliferated, as have the applications for which they are used. Advancements in applications such as satellites, electric vehicles, medical implants, dental aligners, chip manufacturing, carbon capture — 3D printing is playing an integral role in each one — all made possible by Chuck taking the first step with SLA. I’m inspired by his passion and believe we’ll see the possibility of bioprinted human organs becoming a reality in his lifetime. It’s a pleasure to collaborate with Chuck and I am so very grateful and privileged to call him a colleague and friend.”
Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.
About 3D Systems
More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods. More information on the company is available at www.3dsystems.com.